Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in JAMA Oncol Retrieve available abstracts of 106 articles: HTML format

Single Articles

July 2021
1. GETTINGER SN, Redman MW, Bazhenova L, Hirsch FR, et al
   Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
   JAMA Oncol. 2021 Jul 15. pii: 2781889. doi: 10.1001/jamaoncol.2021.2209.
   PubMed     Abstract available
   
   
   
2. BARTELS F, Wandrey MM, Aigner A, Stronisch T, et al
   Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer.
   JAMA Oncol. 2021 Jul 1. pii: 2781389. doi: 10.1001/jamaoncol.2021.2049.
   PubMed     Abstract available
   
   
   
3. JACOBSON JO
   Accompanying Patients in the Time of COVID-19.
   JAMA Oncol. 2021;7:971-972.
   PubMed    
   
   
   June 2021
4. HUI Z, Men Y, Hu C, Kang J, et al
   Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
   JAMA Oncol. 2021 Jun 24. pii: 2781087. doi: 10.1001/jamaoncol.2021.1910.
   PubMed     Abstract available
   
   
   
5. JABBOUR SK, Lee KH, Frost N, Breder V, et al
   Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
   JAMA Oncol. 2021 Jun 4. pii: 2780855. doi: 10.1001/jamaoncol.2021.2301.
   PubMed     Abstract available
   
   
   
6. TAKSLER GB, Peterse EFP, Willems I, Ten Haaf K, et al
   Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
   JAMA Oncol. 2021;7:885-894.
   PubMed     Abstract available
   
   
   May 2021
7. CORBETT K, Sharma A, Pond GR, Brastianos PK, et al
   Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.
   JAMA Oncol. 2021 May 20. pii: 2780060. doi: 10.1001/jamaoncol.2021.1359.
   PubMed    
   
   
   April 2021
8. SUN L, Tan M, Cohen RB, Langer CJ, et al
   Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.
   JAMA Oncol. 2021 Apr 15. pii: 2778198. doi: 10.1001/jamaoncol.2021.0546.
   PubMed    
   
   
   
9. KAMRAN SC, Yeap BY, Ulysse CA, Cronin C, et al
   Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
   JAMA Oncol. 2021 Apr 8. pii: 2778095. doi: 10.1001/jamaoncol.2021.0281.
   PubMed     Abstract available
   
   
   
10. WANG J, Lu S, Yu X, Hu Y, et al
    Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Apr 1. pii: 2777901. doi: 10.1001/jamaoncol.2021.0366.
    PubMed     Abstract available
    
    
    
11. OSAROGIAGBON RU
    Tislelizumab-A Promising New Option for Enhancing Chemotherapy Benefit in Treatment for Advanced Squamous Cell Lung Cancer.
    JAMA Oncol. 2021 Apr 1. pii: 2777904. doi: 10.1001/jamaoncol.2021.0262.
    PubMed    
    
    
    March 2021
12. ZENKE Y, Tsuboi M, Chiba Y, Tsujino K, et al
    Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Mar 18. pii: 2777344. doi: 10.1001/jamaoncol.2021.0113.
    PubMed     Abstract available
    
    
    
13. ITO FUKUNAGA M, Wiener RS, Slatore CG
    The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening: The More Things Stay the Same....
    JAMA Oncol. 2021 Mar 9. pii: 2777056. doi: 10.1001/jamaoncol.2020.8376.
    PubMed    
    
    
    February 2021
14. SINGH H, Pazdur R
    Contribution of Early Clinical Benefit End Points to Decreased Lung Cancer Mortality Rates.
    JAMA Oncol. 2021 Feb 25. pii: 2776763. doi: 10.1001/jamaoncol.2020.8090.
    PubMed    
    
    
    
15. PATHAK R, Boffa DJ
    Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2021 Feb 25. pii: 2776759. doi: 10.1001/jamaoncol.2020.8194.
    PubMed    
    
    
    
16. DAI J, Jin K, Jiang G
    Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Feb 25. pii: 2776757. doi: 10.1001/jamaoncol.2020.8186.
    PubMed    
    
    
    
17. INAMURA K
    Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Feb 25. pii: 2776758. doi: 10.1001/jamaoncol.2020.8189.
    PubMed    
    
    
    
18. PENNELL NA
    Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor-Mutant Lung Cancer.
    JAMA Oncol. 2021 Feb 4. pii: 2775934. doi: 10.1001/jamaoncol.2020.6755.
    PubMed    
    
    
    
19. ASCHELE C, Negru ME, Pastorino A, Cavanna L, et al
    Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy.
    JAMA Oncol. 2021;7:304-306.
    PubMed    
    
    
    
20. WANG Q, Berger NA, Xu R
    Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection.
    JAMA Oncol. 2021;7:220-227.
    PubMed     Abstract available
    
    
    January 2021
21. AKAMATSU H, Toi Y, Hayashi H, Fujimoto D, et al
    Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomiz
    JAMA Oncol. 2021 Jan 7. pii: 2774521. doi: 10.1001/jamaoncol.2020.6758.
    PubMed     Abstract available
    
    
    December 2020
22. ATKINS KM, Chaunzwa TL, Lamba N, Bitterman DS, et al
    Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Dec 17. pii: 2773837. doi: 10.1001/jamaoncol.2020.6332.
    PubMed     Abstract available
    
    
    
23. SIEGEL DA, Fedewa SA, Henley SJ, Pollack LA, et al
    Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States.
    JAMA Oncol. 2020 Dec 3. pii: 2773380. doi: 10.1001/jamaoncol.2020.6362.
    PubMed    
    
    
    
24. SCHOENFELD AJ, Yu HA
    Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply.
    JAMA Oncol. 2020;6:1983.
    PubMed    
    
    
    
25. QI C, Cui H, Chen D
    Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers.
    JAMA Oncol. 2020;6:1982.
    PubMed    
    
    
    November 2020
26. SIMONE CB 2ND
    Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases.
    JAMA Oncol. 2020 Nov 12. pii: 2772840. doi: 10.1001/jamaoncol.2020.5466.
    PubMed    
    
    
    
27. RUSTHOVEN CG, Brown PD, Robin TP
    Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases-Reply.
    JAMA Oncol. 2020 Nov 12. pii: 2772841. doi: 10.1001/jamaoncol.2020.5473.
    PubMed    
    
    
    October 2020
28. SHANKAR B, Zhang J, Naqash AR, Forde PM, et al
    Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Oct 29. pii: 2772169. doi: 10.1001/jamaoncol.2020.5012.
    PubMed     Abstract available
    
    
    
29. ZHANG J, Fu J, Zhang G
    Assessing Expression of PD-L1 in Tumor-Associated Macrophages.
    JAMA Oncol. 2020;6:1634.
    PubMed    
    
    
    
30. JABBOUR S, Simone CB 2nd, Malhotra J
    Assessing Expression of PD-L1 in Tumor-Associated Macrophages-Reply.
    JAMA Oncol. 2020;6:1634-1635.
    PubMed    
    
    
    September 2020
31. BLAYNEY DW, Zhang Q, Feng J, Zhao Y, et al
    Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2020 Sep 24. pii: 2770700. doi: 10.1001/jamaoncol.2020.4429.
    PubMed     Abstract available
    
    
    
32. ELKRIEF A, Kazandjian S, Bouganim N
    Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease 2019 Pandemic.
    JAMA Oncol. 2020 Sep 17. pii: 2770258. doi: 10.1001/jamaoncol.2020.4408.
    PubMed    
    
    
    
33. PATHAK R, Goldberg SB, Canavan M, Herrin J, et al
    Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.
    JAMA Oncol. 2020 Sep 17. pii: 2770263. doi: 10.1001/jamaoncol.2020.4232.
    PubMed     Abstract available
    
    
    July 2020
34. SANTANA-DAVILA R
    Hyperprogressive Disease After Treatment With Checkpoint Inhibitors: Time for Prospective Studies.
    JAMA Oncol. 2020;6:1046-1047.
    PubMed    
    
    
    
35. YU HA, Schoenfeld AJ, Makhnin A, Kim R, et al
    Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
    JAMA Oncol. 2020;6:1048-1054.
    PubMed     Abstract available
    
    
    
36. TAKVORIAN SU, Ladage VP, Wileyto EP, Mace DS, et al
    Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology.
    JAMA Oncol. 2020;6:1104-1106.
    PubMed    
    
    
    June 2020
37. KAS B, Talbot H, Ferrara R, Richard C, et al
    Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 11. pii: 2766806. doi: 10.1001/jamaoncol.2020.1634.
    PubMed     Abstract available
    
    
    
38. LE PECHOUX C, Levy A
    Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases: A Call for Prospective Evidence.
    JAMA Oncol. 2020 Jun 4. pii: 2766562. doi: 10.1001/jamaoncol.2020.1245.
    PubMed    
    
    
    
39. RUSTHOVEN CG, Yamamoto M, Bernhardt D, Smith DE, et al
    Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.
    JAMA Oncol. 2020 Jun 4. pii: 2766565. doi: 10.1001/jamaoncol.2020.1271.
    PubMed     Abstract available
    
    
    
40. BERCHUCK JE, Meyer CS, Zhang N, Berchuck CM, et al
    Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 4. pii: 2766567. doi: 10.1001/jamaoncol.2020.1466.
    PubMed     Abstract available
    
    
    May 2020
41. MIYAMOTO S, Azuma K, Ishii H, Bessho A, et al
    Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    JAMA Oncol. 2020 May 14:e201250. doi: 10.1001/jamaoncol.2020.1250.
    PubMed     Abstract available
    
    
    
42. LIU Y, Colditz GA, Kozower BD, James A, et al
    Association of Medicaid Expansion Under the Patient Protection and Affordable Care Act With Non-Small Cell Lung Cancer Survival.
    JAMA Oncol. 2020 May 14. pii: 2765753. doi: 10.1001/jamaoncol.2020.1040.
    PubMed    
    
    
    April 2020
43. SANCHEZ A, Furberg H
    Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy.
    JAMA Oncol. 2020 Apr 23. pii: 2764900. doi: 10.1001/jamaoncol.2020.0634.
    PubMed    
    
    
    
44. KICHENADASSE G, Hopkins AM, Sorich MJ
    Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy-Reply.
    JAMA Oncol. 2020 Apr 23. pii: 2764902. doi: 10.1001/jamaoncol.2020.0643.
    PubMed    
    
    
    
45. RIZVI NA, Cho BC, Reinmuth N, Lee KH, et al
    Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2020 Apr 9. pii: 2763864. doi: 10.1001/jamaoncol.2020.0237.
    PubMed     Abstract available
    
    
    
46. WAQAR SN, Govindan R
    The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy.
    JAMA Oncol. 2020 Apr 9. pii: 2763860. doi: 10.1001/jamaoncol.2020.0264.
    PubMed    
    
    
    
47. ARRIETA O, Barron F, Ramirez-Tirado LA, Zatarain-Barron ZL, et al
    Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2020 Apr 9. pii: 2763865. doi: 10.1001/jamaoncol.2020.0409.
    PubMed     Abstract available
    
    
    
48. LION AH
    First Rites-A Spiritual History Case Study.
    JAMA Oncol. 2020;6:475-476.
    PubMed    
    
    
    March 2020
49. YANG JJ, Yu D, Shu XO
    Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk-Reply.
    JAMA Oncol. 2020 Mar 19. pii: 2762588. doi: 10.1001/jamaoncol.2020.0270.
    PubMed    
    
    
    
50. WU Q, Leung EL
    Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk.
    JAMA Oncol. 2020 Mar 19. pii: 2762586. doi: 10.1001/jamaoncol.2020.0261.
    PubMed    
    
    
    
51. ARRIETA O, Ramirez-Tirado LA, Zatarain-Barron ZL
    Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2020 Mar 12. pii: 2762582. doi: 10.1001/jamaoncol.2020.0062.
    PubMed    
    
    
    
52. GAO C, Cai S, He Y
    Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Mar 12. pii: 2762581. doi: 10.1001/jamaoncol.2020.0059.
    PubMed    
    
    
    
53. OKAMOTO I, Nokihara H, Nomura S, Niho S, et al
    Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2020 Mar 12:e196828. doi: 10.1001/jamaoncol.2019.6828.
    PubMed     Abstract available
    
    
    
54. FEHLMANN T, Kahraman M, Ludwig N, Backes C, et al
    Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients.
    JAMA Oncol. 2020 Mar 5. pii: 2761984. doi: 10.1001/jamaoncol.2020.0001.
    PubMed     Abstract available
    
    
    
55. TERUYA H, Mukaigawara M, Hirata K
    Progressive Dyspnea in a Woman With Genital Skin Lesions.
    JAMA Oncol. 2020;6:433-434.
    PubMed    
    
    
    
56. ROUSSEAU P
    One Patient's Perspective on Terminal Cancer-Sometimes It Is Best Not to See.
    JAMA Oncol. 2020;6:329.
    PubMed    
    
    
    February 2020
57. JABBOUR SK, Berman AT, Decker RH, Lin Y, et al
    Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2020 Feb 20. pii: 2761665. doi: 10.1001/jamaoncol.2019.6731.
    PubMed     Abstract available
    
    
    
58. LU S, Wang H, Taube JM
    Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply.
    JAMA Oncol. 2020;6:299.
    PubMed    
    
    
    
59. KAZANDJIAN D, Gong Y, Blumenthal GM
    Application of the Lung Immune Prognostic Index From Research to Clinical Practice-Reply.
    JAMA Oncol. 2020;6:300-301.
    PubMed    
    
    
    
60. LONG J, Lin J, Zhao H
    Application of the Lung Immune Prognostic Index From Research to Clinical Practice.
    JAMA Oncol. 2020;6:299-300.
    PubMed    
    
    
    
61. LIU S, Niu W
    Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies.
    JAMA Oncol. 2020;6:298-299.
    PubMed    
    
    
    January 2020
62. SKELIN M, Javor E, Lucijanic M
    Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2020 Jan 16. pii: 2758573. doi: 10.1001/jamaoncol.2019.6295.
    PubMed    
    
    
    
63. SULLIVAN DR, Slatore CG
    Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer-Reply.
    JAMA Oncol. 2020 Jan 16. pii: 2758574. doi: 10.1001/jamaoncol.2019.6301.
    PubMed    
    
    
    December 2019
64. KICHENADASSE G, Miners JO, Mangoni AA, Rowland A, et al
    Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Dec 26. pii: 2757521. doi: 10.1001/jamaoncol.2019.5241.
    PubMed     Abstract available
    
    
    October 2019
65. YANG JJ, Yu D, Xiang YB, Blot W, et al
    Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis.
    JAMA Oncol. 2019 Oct 24. pii: 2753175. doi: 10.1001/jamaoncol.2019.4107.
    PubMed     Abstract available
    
    
    September 2019
66. SULLIVAN DR, Chan B, Lapidus JA, Ganzini L, et al
    Association of Early Palliative Care Use With Survival and Place of Death Among Patients With Advanced Lung Cancer Receiving Care in the Veterans Health Administration.
    JAMA Oncol. 2019 Sep 19. pii: 2751526. doi: 10.1001/jamaoncol.2019.3105.
    PubMed     Abstract available
    
    
    
67. SYKES DB
    Insights From a Patient With Lung Cancer-Party Therapy Is Way Better Than Chemotherapy.
    JAMA Oncol. 2019 Sep 12. pii: 2749689. doi: 10.1001/jamaoncol.2019.2591.
    PubMed    
    
    
    
68. YIN G, Zhang C
    Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Sep 5. pii: 2749254. doi: 10.1001/jamaoncol.2019.3593.
    PubMed    
    
    
    
69. SUN A, Hu C
    Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer-In Reply.
    JAMA Oncol. 2019 Sep 5. pii: 2749255. doi: 10.1001/jamaoncol.2019.3602.
    PubMed    
    
    
    August 2019
70. RENGAN R, Mick R, Pryma DA, Lin LL, et al
    Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.
    JAMA Oncol. 2019 Aug 22. pii: 2748893. doi: 10.1001/jamaoncol.2019.2095.
    PubMed     Abstract available
    
    
    
71. CATANIA C, Del Signore E, Spitaleri G
    The Desire for Life and Motherhood Despite Metastatic Lung Cancer.
    JAMA Oncol. 2019 Aug 15. pii: 2748397. doi: 10.1001/jamaoncol.2019.2588.
    PubMed    
    
    
    
72. STINCHCOMBE TE, Janne PA, Wang X, Bertino EM, et al
    Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2019 Aug 8. pii: 2747878. doi: 10.1001/jamaoncol.2019.1847.
    PubMed     Abstract available
    
    
    July 2019
73. TOPALIAN SL, Hodi FS, Brahmer JR, Gettinger SN, et al
    Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
    JAMA Oncol. 2019 Jul 25. pii: 2738775. doi: 10.1001/jamaoncol.2019.2187.
    PubMed     Abstract available
    
    
    
74. KAZANDJIAN D, Gong Y, Keegan P, Pazdur R, et al
    Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Jul 25. pii: 2738768. doi: 10.1001/jamaoncol.2019.1747.
    PubMed     Abstract available
    
    
    
75. BAUML JM, Mick R, Ciunci C, Aggarwal C, et al
    Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
    JAMA Oncol. 2019 Jul 11. pii: 2738063. doi: 10.1001/jamaoncol.2019.1449.
    PubMed     Abstract available
    
    
    
76. THEELEN WSME, Peulen HMU, Lalezari F, van der Noort V, et al
    Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2019 Jul 11. pii: 2738064. doi: 10.1001/jamaoncol.2019.1478.
    PubMed     Abstract available
    
    
    June 2019
77. ALDRICH MC, Mercaldo SF, Sandler KL, Blot WJ, et al
    Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers.
    JAMA Oncol. 2019 Jun 27. pii: 2737091. doi: 10.1001/jamaoncol.2019.1402.
    PubMed     Abstract available
    
    
    
78. SALEM A, Faivre-Finn C
    Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?-In Reply.
    JAMA Oncol. 2019 Jun 20. pii: 2736365. doi: 10.1001/jamaoncol.2019.1332.
    PubMed    
    
    
    
79. CHUN SG, Schild SE, Bogart JA
    Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?
    JAMA Oncol. 2019 Jun 20. pii: 2736364. doi: 10.1001/jamaoncol.2019.1326.
    PubMed    
    
    
    May 2019
80. GIRI S, Huntington SF
    Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 May 16. pii: 2733792. doi: 10.1001/jamaoncol.2019.1088.
    PubMed    
    
    
    
81. CRISS SD, Mooradian MJ, Kong CY
    Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply.
    JAMA Oncol. 2019 May 16. pii: 2733793. doi: 10.1001/jamaoncol.2019.1100.
    PubMed    
    
    
    April 2019
82. BERNER F, Bomze D, Diem S, Ali OH, et al
    Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Apr 25. pii: 2731134. doi: 10.1001/jamaoncol.2019.0402.
    PubMed     Abstract available
    
    
    March 2019
83. MOR V, Wagner TH, Levy C, Ersek M, et al
    Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer.
    JAMA Oncol. 2019 Mar 28. pii: 2729064. doi: 10.1001/jamaoncol.2019.0081.
    PubMed     Abstract available
    
    
    
84. SUN A, Hu C, Wong SJ, Gore E, et al
    Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2019 Mar 14. pii: 2728245. doi: 10.1001/jamaoncol.2018.7220.
    PubMed     Abstract available
    
    
    February 2019
85. WANG Z, Duan J, Cai S, Han M, et al
    Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    JAMA Oncol. 2019 Feb 28. pii: 2726029. doi: 10.1001/jamaoncol.2018.7098.
    PubMed     Abstract available
    
    
    
86. PALMA DA, Nguyen TK, Louie AV, Malthaner R, et al
    Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
    JAMA Oncol. 2019 Feb 21. pii: 2725402. doi: 10.1001/jamaoncol.2018.6993.
    PubMed     Abstract available
    
    
    December 2018
87. TOI Y, Sugawara S, Sugisaka J, Ono H, et al
    Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Dec 27. pii: 2718925. doi: 10.1001/jamaoncol.2018.5860.
    PubMed     Abstract available
    
    
    
88. CRISS SD, Mooradian MJ, Sheehan DF, Zubiri L, et al
    Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    JAMA Oncol. 2018 Dec 13. pii: 2718006. doi: 10.1001/jamaoncol.2018.5449.
    PubMed     Abstract available
    
    
    
89. SALEM A, Mistry H, Hatton M, Locke I, et al
    Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2018 Dec 6:e185335. doi: 10.1001/jamaoncol.2018.5335.
    PubMed     Abstract available
    
    
    
90. WEST HJ
    Moving Beyond Limited and Extensive Staging of Small Cell Lung Cancer.
    JAMA Oncol. 2018 Dec 6. pii: 2717231. doi: 10.1001/jamaoncol.2018.5187.
    PubMed    
    
    
    November 2018
91. CHEN XZ
    Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.
    JAMA Oncol. 2018 Nov 29. pii: 2716809. doi: 10.1001/jamaoncol.2018.5526.
    PubMed    
    
    
    
92. SLOAN L, Romo CG, Hales RK
    Hemifacial Hyperhidrosis in a Patient With an Apical Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Nov 15. pii: 2713851. doi: 10.1001/jamaoncol.2018.4597.
    PubMed    
    
    
    October 2018
93. EZE C, Kasmann L, Manapov F
    Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 25. pii: 2707226. doi: 10.1001/jamaoncol.2018.4833.
    PubMed    
    
    
    
94. GYAWALI B, West HJ
    Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither?
    JAMA Oncol. 2018 Oct 11. pii: 2705603. doi: 10.1001/jamaoncol.2018.4304.
    PubMed    
    
    
    
95. AGGARWAL C, Thompson JC, Black TA, Katz SI, et al
    Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 11. pii: 2705609. doi: 10.1001/jamaoncol.2018.4305.
    PubMed     Abstract available
    
    
    
96. BOOZALIS E, Kwatra SG, Marrone KA
    Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 4. pii: 2704206. doi: 10.1001/jamaoncol.2018.4485.
    PubMed    
    
    
    September 2018
97. TUMINELLO S, Schwartz RM, Liu B, Mhango G, et al
    Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung Cancer.
    JAMA Oncol. 2018 Sep 24. pii: 2703444. doi: 10.1001/jamaoncol.2018.4387.
    PubMed    
    
    
    
98. FERRARA R, Mezquita L, Texier M, Lahmar J, et al
    Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    JAMA Oncol. 2018 Sep 6. pii: 2698845. doi: 10.1001/jamaoncol.2018.3676.
    PubMed     Abstract available
    
    
    August 2018
99. GRIDELLI C, de Castro Carpeno J, Dingemans AC, Griesinger F, et al
    Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486.
    PubMed     Abstract available
    
    
    
100. HAN B, Li K, Wang Q, Zhang L, et al
     Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
     JAMA Oncol. 2018 Aug 9. pii: 2696341. doi: 10.1001/jamaoncol.2018.3039.
     PubMed     Abstract available
     
     
     
101. ALCORN SR, Miller DB, Hales RK
     Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer.
     JAMA Oncol. 2018 Aug 2. pii: 2694876. doi: 10.1001/jamaoncol.2018.3261.
     PubMed    
     
     
     
102. PASQUINELLI MM, Kovitz KL, Koshy M, Menchaca MG, et al
     Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial.
     JAMA Oncol. 2018 Aug 2. pii: 2694875. doi: 10.1001/jamaoncol.2018.2823.
     PubMed    
     
     
     
103. CHUN SG, Pezzi TA, Schwartz DL
     Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer-Reply.
     JAMA Oncol. 2018 Aug 2. pii: 2694877. doi: 10.1001/jamaoncol.2018.3292.
     PubMed    
     
     
     
104. OXNARD GR, Hu Y, Mileham KF, Husain H, et al
     Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
     JAMA Oncol. 2018 Aug 2. pii: 2694879. doi: 10.1001/jamaoncol.2018.2969.
     PubMed     Abstract available
     
     
     July 2018
105. GUIDA F, Sun N, Bantis LE, Muller DC, et al
     Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
     JAMA Oncol. 2018 Jul 12:e182078. doi: 10.1001/jamaoncol.2018.2078.
     PubMed     Abstract available
     
     
     June 2018
106. GANDARA DR, Riess JW, Lara PN Jr
     In Search of an Oncogene Driver for Squamous Lung Cancer.
     JAMA Oncol. 2018 Jun 14. pii: 2684629. doi: 10.1001/jamaoncol.2018.0774.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: